Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis - CME - Guideline Central

CME

Title
Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis
Link
Description
The neonatal Fc receptor (FcRn) preserves IgG by preventing lysosomal degradation, thereby extending IgG half-life. Inhibition of FcRn enhances the clearance of pathogenic IgG autoantibodies, resulting in rapid and reversible reductions in circulating AChR and MuSK antibodies without causing broad immunosuppression. This educational program for neurologists delivers a focused, clinically relevant update on FcRn blockade in the management of generalized myasthenia gravis (gMG), highlighting the pathophysiologic rationale for targeting FcRn and its translation into meaningful patient benefit.
Target Audience
This educational activity is directed toward neurologists, neurology nurses, specialty nurse practitioners and physician assistants, and other health care practitioners involved in managing generalized myasthenia gravis
Learning Objectives
  • Outline the role of FcRN in the pathophysiology of generalized myasthenia gravis
  • Evaluate emerging data for FcRN-targeted therapies for generalized myasthenia gravis in relation to treatment outcomes
  • Integrate novel agents into individualized multidisciplinary management plans for patients with generalized myasthenia gravis
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Neurology
Keywords
generalized myasthenia gravis (gMG)
Disclosures and Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
Accredited Providers
  • Physicians’ Education Resource
Commercial Support
  • UCB Pharma Inc
Activity Expiration Date
December 23, 2026
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.